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αB-crystallin, a small heat-shock protein, exhibits molecular cha-
perone activity. We have studied the effect of αB-crystallin on the
fibril growth of the Aβ (amyloid β)-peptides Aβ-(1–40) and Aβ-
(1–42). αB-crystallin, but not BSA or hen egg-white lysozyme,
prevented the fibril growth of Aβ-(1–40), as revealed by thioflavin
T binding, total internal reflection fluorescence microscopy and
CD spectroscopy. Comparison of the activity of some mutants
and chimaeric α-crystallins in preventing Aβ-(1–40) fibril growth
with their previously reported chaperone ability in preventing di-
thiothreitol-induced aggregation of insulin suggests that there
might be both common and distinct sites of interaction on α-
crystallin involved in the prevention of amorphous aggregation of
insulin and fibril growth of Aβ-(1–40). αB-crystallin also prevents
the spontaneous fibril formation (without externally added seeds)
of Aβ-(1–42), as well as the fibril growth of Aβ-(1–40) when
seeded with the Aβ-(1–42) fibril seed. Sedimentation velocity
measurements show that αB-crystallin does not form a stable com-
plex with Aβ-(1–40). The mechanism by which it prevents the
fibril growth differs from the known mechanism by which it pre-
vents the amorphous aggregation of proteins. αB-crystallin binds
to the amyloid fibrils of Aβ-(1–40), indicating that the preferential
interaction of the chaperone with the fibril nucleus, which inhibits
nucleation-dependent polymerization of amyloid fibrils, is the
mechanism that is predominantly involved. We found that αB-
crystallin prevents the fibril growth of β2-microglobulin under
acidic conditions. It also retards the depolymerization of β2-
microglobulin fibrils, indicating that it can interact with the fibrils.
Our study sheds light on the role of small heat-shock proteins
in protein conformational diseases, particularly in Alzheimer’s
disease.
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INTRODUCTION
αB-crystallin, an abundant eye lens protein, is also present in other
tissues and is heat- and stress-inducible, whereas αA-crystallin,
the other eye lens protein, is not heat-inducible [1–4]. Both αA-
and αB-crystallin (subunit molecular mass ≈20 kDa) form homo-
as well as hetero-multimers of various sizes [5], and exhibit mole-
cular-chaperone-like activity in preventing aggregation of other
proteins [6–9], with αB-crystallin being more efficient than αA-
crystallin [8,9]. They belong to the sHsp (small heat-shock pro-
tein) family. Primary sequence analysis of sHsps divides the
sequence into three parts [11]: a highly conserved central region
(≈80 residues), rich in β-strands, called the ‘α-crystallin domain’,
which is flanked by an N-terminal domain and a C-terminal
extension, which vary considerably both in their sequence and
length [11]. The N-terminal domain as well as the α-crystallin do-
main has sites for target protein binding [12]. The C-terminal ex-
tensions, previously believed to function as ‘solubilizers’ of the
chaperone–target protein complex, also play an important role in
its chaperone-like activity [13].
Aggregation of proteins can be classified into two types:
(i) well-ordered amyloid fibril formation with intermolecular β-
sheet structure [14]; and (ii) irregular or amorphous aggregation.
The molecular-chaperone-like activity of α-crystallin towards the
amorphous aggregation and precipitation of other proteins has
been the subject of intense research, since this property is crucial
for maintaining eye lens transparency [6]. Failure of the activity
of α-crystallin, owing to either post-translational age-dependent
modifications or mutations, may be involved in cataract formation
[2]. However, its effect on well-ordered amyloid fibril formation is
not completely understood.
αB-crystallin is present in brain tissues, and its expression
is elevated in several neurodegenerative diseases, such as
Parkinson’s disease, CJD (Creutzfeldt–Jakob disease) and AD
(Alzheimer’s disease) [15,16]. AD is a progressive neurodegen-
erative disease characterized by cerebral deposits of extracellular
amyloid plaques, intracellular tangles and intra- or extra-vascu-
lar deposits [17]. αB-crystallin is found to co-exist in these
deposits [18], along with the amyloid fibrils of a mixture of 39–43-
amino-acid polypeptides, generally designated as Aβ (amyloid
β)-peptides, produced from proteolytic processing of the amy-
loid precursor protein [19]. One of the Aβ peptides comprising
40-amino-acid residues [Aβ-(1–40)] constitutes approx. 90% of
the total Aβ peptides [20]. The increase in levels of αB-crystallin
found in AD reveals an important role of the sHsp(s) in AD.
Calf eye lens α-crystallin has been shown to prevent the fibril
formation of model systems, such as apolipoprotein [21] and α1-
antichymotrypsin [22]. However, Kudva et al. [23] have reported
that αB-crystallin has no effect on the amyloid fibril formation of
Aβ-(1–42), whereas Hsp27, another sHsp, was shown to prevent
amyloid formation. Liang [24] has reported that the interaction
between Aβ-(1–40) and αB-crystallin leads to promotion of fibril
formation. On the other hand, Stege et al. [25] have concluded
that the presence of calf eye lens αB-crystallin does not lead to
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fibril but proto-fibril formation of an Aβ peptide. Thus the role of
αB-crystallin in the amyloid fibril formation of Aβ peptide still
remains elusive.
The mechanism for amyloid fibril formation involves two im-
portant steps: nucleation and propagation [26]. We have studied
the effect of recombinant human αB- and αA-crystallin, their
mutants and engineered α-crystallins on the amyloid fibril propa-
gation of Aβ-(1–40) after providing the required nucleation using
the sonicated fibril seed, as well as on the spontaneous fibril for-
mation (without externally added seeds) of Aβ-(1–42). We have
also studied fibril growth of a larger polypeptide, β2m (β2-
microglobulin), a constituent of the class I MHC, which is
involved in dialysis-related amyloidosis [27]. β2m fibrils form
under acidic conditions [28] and depolymerize upon shifting the
pH to neutral [29]. Thus β2m may serve as a good model system
to study the effect of α-crystallin on such a fibril growth and
depolymerization process. Our study demonstrates that the sHsp
α-crystallin prevents the amyloid fibril growth of Aβ-(1–40), Aβ-
(1–42) and β2m, and also reveals, for the first time, the underlying
mechanism.
EXPERIMENTAL
Materials
Recombinant human αA- and αB-crystallin, R120G-αB-crys-
tallin (a mutant that causes desmin-related myopathy and con-
genital cataract [30]) and the deletion mutant αBdel, in which
the conserved SRLFDQFFG residues in the N-terminal region
have been deleted, and the chimaeric proteins, αANBC-crystallin
(comprising the N-terminal domain of αA- and the C-terminal
domain of αB-crystallin) and αBNAC-crystallin (comprising the
N-terminal domain of αB- and the C-terminal domain of αA-
crystallin), were expressed in Escherichia coli and purified to
homogeneity, as described in earlier studies by Rao and col-
leagues [31–33]. Human Aβ-(1–40) was purchased from the
Peptide Institute, Inc., Osaka, Japan. Human Aβ-(1–42) was
purchased from Sigma Chemical Co. (St Louis, MO, U.S.A.). The
monomeric recombinant human β2m was expressed in E. coli and
purified to homogeneity, as described previously [34]. Fatty acid-
free BSA and HEWL (hen egg-white lysozyme) were purchased
from Sigma Chemical Co.
Amyloid fibril growth of Aβ-(1–40)
Aβ-(1–40) peptide (50 µM; ≈0.22 mg/ml) in 50 mM sodium
phosphate buffer, pH 7.4, containing 100 mM NaCl (referred to
hereafter as buffer A), in the absence or in the presence of indi-
cated concentrations of α-crystallins or other proteins, was incu-
bated at 37 ◦C with 5 µg/ml sonicated, preformed amyloid fibrils
(hereafter referred to as ‘fibril seed’). Aliquots (5 µl) of the
sample were withdrawn at different time points and added to
1 ml of 5 µM Tht (thioflavin T) in 50 mM glycine/NaOH buffer,
pH 8.5 (referred to hereafter as ThT solution). Fluorescence
intensity of the sample at 485 nm, which is proportional to the
extent of amyloid fibril-bound ThT [35] and hence the amyloid
fibril growth, was measured using a Hitachi F-4500 fluorescence
spectrophotometer with an excitation wavelength of 445 nm.
We have also tested the fibril growth of Aβ-(1–40) using
the sonicated fibril seed of Aβ-(1–42) (20 µg/ml) under similar
conditions. Aβ-(1–42) fibrils are formed by incubating 50 µM of
the peptide in buffer A at 37 ◦C for 7 h. The effect of α-crystallin
on the spontaneous fibril formation (without externally adding
seeds) of Aβ-(1–42) was studied by incubating 50 µM
(≈0.23 mg/ml) Aβ-(1–42) in the absence and in the presence of
indicated concentrations of α-crystallins at 37 ◦C. Small aliquots
of the sample were withdrawn at different time points, and ThT
binding was studied as described above. All experiments were re-
peated three times, and the results were found to be reproducible.
Representative data are shown.
Amyloid fibril growth of β2m
The seed-dependent elongation of β2m fibrils was performed es-
sentially following the method described previously [28]. Mono-
meric β2m (25 µM) in 50 mM sodium citrate buffer, pH 2.5,
containing 100 mM NaCl either in the absence or the presence
of indicated concentrations of α-crystallins or other proteins, was
incubated together with its 5 µg/ml fibril seed at 37 ◦C. Aliquots
(10 µl) of the sample were withdrawn at different time intervals
and added to 1 ml of 5 µM ThT solution, and their fluorescence
intensities were measured as described above. A similar experi-
ment was performed at pH 5.3 using the buffer system of 25 mM
sodium phosphate/citric acid containing 100 mM Na2SO4.
TIRFM (total internal reflection fluorescence microscopy)
The Aβ sample (10 µl) was mixed with 10 µl of 10 µM ThT
in 100 mM glycine/NaOH buffer, pH 8.5, and the mixture was
placed on a glass slide. The TIRFM system to observe ThT-bound
amyloid fibrils is developed based on an inverted microscope
(IX70; Olympus, Tokyo, Japan) as described previously [36]. ThT
was excited by argon laser (Model 185F02-ADM; Spectra Phy-
sics, Mountain View, CA, U.S.A.). The fluorescent image was
filtered by a band-pass filter (D490/30 Omega Optical; Brat-
tleboro, VT, U.S.A.) and visualized using a digital camera (DP70;
Olympus, Tokyo, Japan).
CD spectroscopy
Either samples of 0.22 mg/ml Aβ peptide alone in buffer A or
samples of the peptide incubated in the absence and presence of
0.1 mg/ml αB-crystallin or BSA at 37 ◦C for 80 min were pre-
pared. These samples were diluted 1:1 (v/v) with buffer A, and
the far-UV CD spectra were recorded at 37 ◦C using a Jasco-600
spectropolarimeter equipped with a thermostat-controlled cell
holder. A quartz cuvette with 0.1 cm path length was used. The
spectral contributions of αB-crystallin or BSA were subtracted
from the spectra of the mixture. The data are shown as the mean
residue mass ellipticity for the Aβ peptide.
Sedimentation velocity
Sedimentation velocity measurements were performed using an
Optima XL-I analytical ultracentrifuge (Beckman Coulter,
Fullerton, CA, U.S.A.) with an An-60 rotor and two-channel, char-
coal-filled Epon cells. Samples (0.3 ml) of 0.08 mg/ml αB-crys-
tallin and 0.16 mg/ml Aβ-(1–40), and their mixture (0.04 and
0.08 mg/ml respectively), in buffer A were incubated at 37 ◦C for
15 min, followed by centrifugation at 42500 g. At these peptide
and protein concentrations, the total absorbance at 225 nm was
approx. 1.0, with protein and peptide contributing approx. 0.5 each
to the mixture. The protein boundary was scanned at 6 min inter-
vals for its absorbance at 225 nm. Boundary curves at 12 min
intervals are shown (see Figure 3). The apparent sedimentation co-
efficient of αB-crystallin in buffer A at 37 ◦C was calculated using
the software Origin 4.1 (Microcal Software, Inc., Northampton,
MA, USA).
Binding of α-crystallin to the amyloid fibrils of Aβ-(1–40)
Samples of αB-crystallin or BSA (0.1 mg/ml) in buffer A in the
absence or in the presence of 0.11 mg/ml amyloid fibrils of Aβ-
(1–40) were incubated at 37 ◦C for 20 min, and then centrifuged
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at 13000 g for 15 min using a Hitachi Himac CF 15R microcentri-
fuge. Aliquots (20 µl) of the supernatant of the sample were di-
luted to 0.3 ml with buffer A, and tryptophan fluorescence spectra
(whose intensity is a measure of αB-crystallin or BSA that is
not bound to the fibrils) were recorded using a Hitachi F-4500
fluorescence spectrophotometer with an excitation wavelength of
295 nm. The excitation and emission band passes were set at 5 nm.
The amount of fibrils in the supernatant after centrifugation was
measured from their ThT fluorescence, and found to be less than
2% in all the samples.
Effect of α-crystallins on β2m amyloid fibril depolymerization
The β2m amyloid fibril formed at pH 2.5 is known to be unstable
upon shifting the pH to neutral [29]. β2m amyloid fibrils were
prepared following a method described previously [28] by incuba-
ting 0.3 mg/ml β2m in 50 mM sodium citrate buffer, pH 2.5, con-
taining 100 mM NaCl together with 5 µg/ml sonicated fibril seed
at 37 ◦C for 4 h. The sample was centrifuged at 13000 g and re-
suspended in the same buffer, so that the stock concentration
of the fibril was 0.6 mg/ml. To study the effect of α-crystallin on
the fibril depolymerization process, buffer A in the absence or
in the presence of required concentrations of α-crystallin or other
indicated proteins was equilibrated at 37 ◦C, and then the β2m
fibrils were added to a final concentration of 0.06 mg/ml. Aliquots
(10 µl) of the samples were withdrawn at indicated time points
and added to 1 ml of ThT solution. The amount of fibrils in the
sample at various time intervals was measured from their ThT
fluorescence. Fractions of the fibrils that were undissociated were
calculated on the basis of the ThT fluorescence intensity of the
samples with respect to their fluorescence intensity immediately
after dilution (zero time).
RESULTS AND DISCUSSION
αB-crystallin prevents the amyloid fibril growth of Aβ-(1–40)
Aβ peptides are known to exhibit nucleation-dependent amyloid
fibril formation [26]. Figure 1 shows that incubation of ≈0.22 mg/
ml synthetic Aβ-(1–40) in buffer A at 37 ◦C with 5 µg/ml fibril
seed leads to progressive amyloid fibril formation, as measured
by the binding of ThT (Figure 1, closed circles). We have investi-
gated the role of αB-crystallin on such nucleated fibril growth
of Aβ peptide. Figure 1(A) shows that αB-crystallin prevents
fibril growth even at the chaperone to Aβ mass ratio of 0.25:1.0.
Although αA-crystallin is also able to prevent the fibril growth
of the peptide, it is relatively less effective than αB-crystallin at
comparable concentrations of the chaperones (cf. Figures 1A and
1B). BSA and HEWL, however, do not prevent the fibril growth
of the Aβ peptide significantly (Figures 1C and 1D), indicating
that the effect of α-crystallin on the Aβ amyloid fibril growth
is specific in nature. We have tested whether αB-crystallin has
any defibrillation activity by incubating the fibrils of Aβ-(1–40)
(0.1 mg/ml) along with αB-crystallin (0.5 mg/ml) at 37 ◦C for
4 h. We did not observe a significant decrease in the ThT fluore-
scence, indicating that αB-crystallin does not exhibit defibrillation
activity (results not shown).
TIRFM has been shown to be useful in visualizing ThT-bound
amyloid fibrils [36]. We examined the samples of ThT-bound fibril
seed, the Aβ amyloid fibrils and the samples of the Aβ peptide and
the seed incubated along with αB-crystallin or BSA by TIRFM
(Figure 2). Amyloid fibril growth of Aβ-(1–40) occurs to differing
lengths of the order of a few micrometres, both in buffer alone and
in the presence of BSA: the fibres grown in the presence of BSA
Figure 1 Effect of αB-crystallin (A), αA-crystallin (B), BSA (C) and HEWL
(D) on the amyloid fibril growth of Aβ-(1–40)
The fibril growth of Aβ-(1–40) (0.22 mg/ml) in buffer alone () and in the presence of
0.05 mg/ml (), 0.1 mg/ml (H17009) or 0.4 mg/ml () of the protein additives.
Figure 2 TIRFM images
Shown are ThT-stained samples of 10 µg/ml Aβ-(1–40) fibril seed (A), and 0.22 mg/ml
Aβ-(1–40) peptide incubated at 37◦C for 2 h with 5 µg/ml fibril seed in the absence (B) or in
the presence of 0.1 mg/ml BSA (C) or αB-crystallin (D). In the cases of fibril grown in buffer
alone and in the presence of 0.1 mg/ml BSA, the amount of fibril was so high that the samples
were diluted four times with buffer A before ThT staining. It should be noted that, in the case of
αB-crystallin, no significant fibrils were seen, despite the fact that the sample was used as such
for ThT staining. The scale bars represent 5 µm.
seem to be longer than those grown in buffer alone (cf. Figure 2B
and 2C). On the other hand, we could see only the added seeds,
but no significant fibrils in the samples containing αB-crystallin
(Figure 2D). Thus the ThT binding and TIRFM results show that
αB-crystallin prevents the growth of Aβ-(1–40) fibrils.
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Figure 3 Far-UV CD spectra
Aβ-(1–40) peptide in buffer A (trace 1), and the sample of 0.22 mg/ml Aβ-(1–40) in buffer A
incubated at 37◦C for 80 min with 5 µg/ml fibril seed in the absence (trace 2) or in the presence
of 0.1 mg/ml αB-crystallin (trace 3) or BSA (trace 4) are shown. The spectral contribution of
αB-crystallin or BSA was subtracted from the corresponding spectrum of the sample. [θ ] is the
mean residue mass ellipticity.
αB-crystallin prevents the induction of β-sheet structure
upon fibril growth
Amyloid fibril exhibits characteristic well-ordered, cross-β-sheet
structure [14]. Fibril propagation thus leads to association-in-
duced generation of β-sheet structure. We have investigated the
effect of αB-crystallin on such association-induced generation of
β-sheet structure of the Aβ peptide. Aβ-(1–40) peptide exhibits
randomly coiled conformation, as revealed by its far UV-CD spec-
trum (Figure 3, trace 1). Incubation of the peptide in the presence
of fibril seed for 80 min generates a characteristic far-UV CD
spectrum for β-sheet structure, with a minimum around 218 nm
(Figure 3, trace 2). However, such induction of β-sheet structure
does not occur in the presence of αB-crystallin (Figure 3, trace 3).
In contrast, induction of β-sheet occurs in the presence of BSA
(Figure 3, trace 4). Thus αB-crystallin specifically prevents the
amyloid fibril growth of the Aβ peptide and the association-
induced generation of β-sheet structure. Monomeric Aβ peptides
are not toxic to the cells [37–40]. Earlier studies have shown that
amyloid fibrils with induced β-sheet are toxic to the cells [37].
Subsequent studies have shown that protofibrils or prefibrillar
oligomers are more toxic to the cells [38–41], whereas the toxicity
depends on the size of the aggregates [40,41]. Prevention of
amyloid fibril formation by the sHsp, αB-crystallin, may thus
serve as one of the protective mechanisms.
αB-crystallin prevents the fibril growth of Aβ-(1–40) seeded by
Aβ-(1–42) fibrils and spontaneous fibril formation of Aβ-(1–42)
We have tested whether αB-crystallin also prevents the fibril
growth of Aβ-(1–40) if seeded with the Aβ-(1–42) fibrils. Under
our experimental conditions, incubation of unseeded solution
of Aβ-(1–40) at 37 ◦C does not lead to significant formation of
fibrils, even after several hours. When seeded with the soni-
cated fibril seeds of Aβ-(1–42), fibril growth occurs progressively,
as measured by ThT fluorescence (Figure 4A). Similar to the
observation in Figure 1, αB-crystallin inhibits the fibril growth
of Aβ-(1–40) seeded with the sonicated Aβ-(1–42) fibrils (Fig-
ure 4A). We have also found that αB-crystallin prevents the
spontaneous fibril formation of Aβ-(1–42) without externally
added seeds (Figure 4B).
Figure 4 Effect of αB-crystallin on the fibril growth of Aβ-(1–40) seeded
with the sonicated fibrils of Aβ-(1–42) (A), and effect of αB-crystallin on the
spontaneous fibril formation of Aβ-(1–42) (B)
(A) Unseeded 0.22 mg/ml Aβ-(1–40) in buffer A (H17009), and the Aβ-(1–40) sample seeded
with 20 µg/ml Aβ-(1–42) fibril seed in the absence () or in the presence () of 0.1 mg/ml
αB-crystallin are shown. (B) Aβ-(1–42) (≈0.23 mg/ml) in the absence () or in the presence
() of 0.1 mg/ml αB-crystallin.
Effects of mutant and chimaeric α-crystallins
We have compared the relative effects of the wild-type, some mu-
tants and chimaeric proteins of αA- and αB-crystallin in pre-
venting the amyloid fibril growth of Aβ-(1–40) at the con-
centration where these proteins offer partial protection. As seen
in Figure 5, except for the chimaeric protein, αBNAC-crystallin
(see the Experimental section), which inhibits completely the
fibril growth, other proteins exhibit marginal differences in their
ability to prevent the fibril growth. However, earlier studies
have shown that they differ drastically in their ability to prevent
the amorphous aggregation of target proteins, such as insulin or
citrate synthase [32]. For example, the chimaeric protein αANBC-
crystallin, which did not prevent the amorphous aggregation of
insulin at all [32], prevents the fibril growth of Aβ-(1–40) to an
extent comparable with that of αA- or αB-crystallin (Figure 5).
Although the deletion mutant, αBdel, exhibits severalfold-in-
creased chaperone-like activity towards the aggregation of insu-
lin or citrate synthase [33], it shows only marginally higher abili-
ty than αB-crystallin to prevent the fibril growth of Aβ-(1–
40) (Figure 5). The mutation of the conserved arginine residue,
R120G, in αB-crystallin leads to significantly decreased chaper-
one-like activity towards insulin aggregation [31], whereas its
ability to prevent the Aβ-(1–40) fibril growth is only marginally
lower than that of αB-crystallin. We have also tested αB-crys-
tallin, R120G-αB-crystallin and αBdel-crystallin on the spon-
taneous fibril formation of Aβ-(1–42) and found that they did
not differ drastically in their ability to prevent the fibril formation
c© 2005 Biochemical Society
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Figure 5 Effect of the wild-type, mutant and engineered α-crystallins in
preventing amyloid fibril growth of Aβ-(1–40)
The percentage prevention of the fibril growth was calculated using the formula [1 − (Fα /F b)] ×
100, where F b and Fα are the ThT fluorescence intensities of samples of 0.22 mg/ml Aβ-(1–40)
incubated at 37◦C for 60 min with 10 µg/ml fibril seed in buffer A alone, or in the presence of
0.05 mg/ml α-crystallins, respectively. Error bars derived from the data for three experiments
are shown. The inset compares the effect of 25 µg/ml αB-crystallin, R120G αB-crystallin and
αBdel-crystallin on the spontaneous fibril formation of Aβ-(1–42) (≈0.23 mg/ml).
(Figure 5, inset). Thus the relative effects of these proteins dif-
fer significantly towards the amorphous aggregation of proteins
and fibril formation of Aβ peptides. These differences could be
because of possible mechanistic differences between the chaper-
one function in preventing amorphous aggregation and amyloid
fibril formation. It is also possible that some common and dis-
tinct chaperone sites are involved in preventing the amorphous
aggregation and amyloid fibril growth of Aβ peptides.
Mechanism involved in the prevention of amyloid fibril growth
by α-crystallin
Our results clearly demonstrate that αB-crystallin prevents the
well-ordered amyloid fibril growth. The prevention of Aβ peptide
fibrillation by α-crystallin may involve either or both of the two
possible mechanisms. (i) α-Crystallin may bind to the amy-
loidogenic species (monomers) of the Aβ peptide and hence pre-
vent their association. α-Crystallins and other Hsps are known
to bind the target proteins to form a stable complex and prevent
aggregation [10]. (ii) α-Crystallin may interact with the fibril seed,
which nucleates the amyloid fibril growth. Such an interaction
may mask the complementary surfaces that are critical for the
assembly of fibril growth. Which of the two mechanisms is opera-
tive in the case of prevention of well-ordered amyloid fibrils is a
pertinent question to be addressed.
We have investigated the possible mechanism of αB-crys-
tallin forming a stable complex with the Aβ peptide by sedi-
mentation velocity measurements, since these two molecules
differ drastically in their molecular masses and hence in their sedi-
mentation coefficients. If the chaperone binds to the amyloido-
genic peptide to form a stable complex, the slow-sedimenting
species of the Aβ peptide should sediment along with the fast-
sedimenting αB-crystallin molecules. The concentrations of the
protein and the peptide have been selected such that the total
absorbance of the sample at 225 nm is approx. 1.0. Figure 6(A)
shows the progressive movement of the boundary of αB-crystallin
sample alone during the ultracentrifugation. On the other hand,
the boundary of the Aβ peptide sample alone does not move
Figure 6 Sedimentation velocity analysis
αB-crystallin (A), Aβ-(1–40) peptide (B) and the mixture of the two (C) in buffer A at 37◦C
are shown. The curves represent the radial scan traces corresponding to every 12 min interval
(from left to right; see the Experimental section for details).
significantly under the same conditions (Figure 6B). If there is
a stable complex formation between these two molecules, we
should not distinctly observe the boundary corresponding to the
Aβ peptide, as it is expected to move along with that of αB-
crystallin in the sample that is a mixture of these two molecules.
However, contrary to this expectation, our result (Figure 6C)
shows that the boundary corresponding to the peptide is distinctly
observed in the mixture of these two molecules; the absorbance
value also does not decrease significantly from the expected value
of approx. 0.5 for half the concentration of the peptide used in the
case of peptide alone (Figure 6B). The apparent sedimentation
coefficient of αB-crystallin in the buffer at 37 ◦C in the absence
or in the presence of Aβ-(1–40) was calculated to be approx.
≈18 S. Thus these results rule out the possibility of the formation
of a stable complex as a predominant mechanism by which
αB-crystallin prevents the amyloid fibril growth of the peptide.
However, transient or reversible interaction of the peptide with α-
crystallin cannot be ruled out. It should be noted that earlier studies
from one of our laboratories showed that α-crystallin binds and
forms stable complexes only with the aggregation-prone molten-
globule-like states of target proteins [42], and does not form
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stable complexes either with compact molten globules with less
exposed hydrophobic surfaces [42] or with the randomly coiled
conformation of reduced RNase A, for example [43]. Aβ peptide
adopts a randomly coiled structure (Figure 3) and it does not form
a stable complex with α-crystallin (Figure 6). The present results
are consistent with our earlier conclusions.
We have investigated the second possibility of αB-crystallin
interacting with the seed fibrils and preventing amyloid propa-
gation. Since the amyloid fibrils sediment at a relatively low
centrifugal force, if there is a stable interaction (binding) of the
chaperone to the fibrils, the concentration of the chaperone in
the supernatant will be decreased, depending on the avidity of the
interaction. Since the Aβ peptide does not contain tryptophan
residues in its sequence, tryptophan fluorescence can be used to
selectively measure the amount of αB-crystallin or BSA (used as
a control) in the supernatant. More than 98% of the amyloid fibrils
of the Aβ peptide sediment under our experimental conditions,
whereas α-crystallins and BSA alone do not sediment. We have
incubated α-crystallin or BSA (0.1 mg/ml) samples in the absence
or in the presence of amyloid fibrils of Aβ-(1–40) (0.1 mg/ml) at
37 ◦C for 20 min, and then centrifuged to remove only the protein
bound to the fibrils. The amount of α-crystallin or BSA in the
supernatant was measured by its intrinsic tryptophan fluorescence,
which represents unbound protein. A remarkable decrease in
fluorescence intensity of the supernatant of the αB-crystallin
samples incubated with the amyloid fibrils was observed (Fig-
ure 7A), indicating that as much as 46% of the αB-crystallin is
bound to the amyloid fibrils of Aβ (Figure 7B, inset). On the other
hand, the fluorescence spectra of the supernatant of the samples
of BSA in the absence or in the presence of the fibrils differ
only marginally (<10%) in terms of the fluorescence intensity
(Figure 7B), indicating that BSA does not interact with the
amyloid fibrils significantly. Corroboration of this result showing
the differential ability of αB-crystallin and BSA to bind the
amyloid fibrils with the results showing their ability to prevent
the amyloid fibril growth (Figure 1) reveals, for the first time, that
binding of αB-crystallin to the fibril seed, which nucleates the
growth of the fibrils, is the predominant mechanism involved in
the prevention of Aβ peptide amyloid propagation by the chaper-
one molecule. In order to understand the generality of the mech-
anism, we have studied the effect of α-crystallins on the fibril
growth and dissociation of β2m.
Effect of α-crystallin on amyloid fibril growth and dissociation
of β2m
β2m is the major component of amyloid deposits found in patients
of haemodialysis-related amyloidosis [27]. This protein readily
undergoes amyloid formation under acidic conditions below pH 4
[28]. The fibrils of β2m formed under acidic conditions dissociate
upon shifting them to neutral pH [29]. Thus β2m serves as another
good model system to investigate whether α-crystallin can interact
with fibrils.
Although, under the extremely acidic conditions where β2m
readily forms fibrils, α-crystallin undergoes denaturation (αB-
crystallin has been shown to dissociate into monomers, whereas
αA-crystallin forms structurally perturbed small multimers [44]),
it was interesting to investigate whether these structurally per-
turbed species of α-crystallin are capable of preventing amy-
loid fibril growth. Figure 8(A) shows that α-crystallin is capable
of preventing the amyloid fibril growth of β2m, even at pH 2.5.
However, the concentrations of α-crystallin required to prevent
amyloid fibril growth of β2m almost completely are compara-
tively higher than those required to prevent the fibrillation of Aβ-
(1–40). BSA also seems to prevent the fibril growth to a significant
Figure 7 Binding of αB-crystallin to the amyloid fibrils of Aβ-(1–40)
measured using the tryptophan fluorescence of αB-crystallin
(A) Tryptophan fluorescence spectra of the supernatant of the αB-crystallin samples (0.1 mg/ml)
in buffer A incubated at 37◦C in the absence (trace 1) and in the presence of 0.11 mg/ml amyloid
fibrils of Aβ-(1–40) (trace 2) after centrifugation to remove the fibrils and bound protein are
shown. (B) Tryptophan fluorescence spectra of the supernatant of the BSA samples (0.1 mg/
ml) in buffer A incubated at 37◦C in the absence (trace 1) or in the presence of the 0.11 mg/ml
amyloid fibrils of Aβ-(1–40) (trace 2) after the centrifugation.
extent, although relatively lower than that of α-crystallin, whereas
HEWL shows no effect on the amyloid fibril growth of β2m at
pH 2.5 (Figure 8A).
Our recent study on the effect of salts on the amyloid fibril
growth of β2m showed that the critical balance of electrostatic
and hydrophobic interactions, modulated by preferential co-solute
anion interaction, is important in the amyloid propagation process
of β2m [45]. We also found that sulphate can promote amyloid
fibril growth between pH 5 and 6, just below its isoelectric point
[45]. As moderately low pH values can occur physiologically
under certain inflammatory conditions, it is probable that circu-
lating β2m may encounter such low-pH conditions [46]. It is
not known whether sHsps such as αB-crystallin are found in the
amyloid deposits of β2m, as observed in other amyloid deposits
involved in several neurodegenerative diseases. However, αB-
crystallin could be detected in blood sera using monoclonal anti-
bodies (S. Rao, V. Pasha, S. Mahesh and M. Rao, unpublished
work). We have investigated whether α-crystallins can prevent the
sulphate-promoted amyloid fibril growth of β2m at pH 5.3 and
found that α-crystallin, indeed, prevented fibril growth under such
moderately acidic conditions (Figure 8B). Although the impli-
cations of these results are not clear at present, the effect of α-
crystallin towards this model system shows that it can prevent
amyloid growth under acidic conditions as well. Since the amyloid
fibril growth of Aβ peptide under acidic conditions is very poor,
we could not study the effect of α-crystallin under such conditions.
Hence our results on the effect of α-crystallin on the amyloid
fibril growth of β2m under acidic conditions can be taken to
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Figure 8 Effect of α-crystallins on the amyloid fibril growth of β2m under
acidic conditions
(A) Amyloid fibril growth in 50 mM sodium citrate buffer, pH 2.5, containing 100 mM NaCl in
the absence () or in the presence of 0.4 mg/ml αA-crystallin (), αB-crystallin (H17009), BSA
() and HEWL (). (B) Sodium sulphate-promoted amyloid fibril growth of β2m at pH 5.3 in
25 mM sodium phosphate–citric acid buffer, pH 5.3, containing 100 mM Na2SO4 alone (), or
in the presence of 0.2 mg/ml αA-crystallin () or αB-crystallin (H17009).
complement our conclusion that αB-crystallin, an sHsp, can
prevent the amyloid fibril growth of small peptides (e.g. Aβ) or
relatively larger proteins (e.g. β2m) under either normal physio-
logical or acidic pH conditions.
We have exploited the property of the β2m fibrils to dissociate
upon shifting them to neutral pH [29] to find out whether α-crys-
tallin can interact with the fibrils of β2m. Interestingly, αB-
crystallin retards the dissociation of the β2m amyloid fibril
(Figure 9, inset). This effect of αB-crystallin appears to be specific
in nature, since BSA and HEWL do not significantly retard
β2m amyloid fibril dissociation at comparable concentrations
(Figure 9). Moreover, the mutants and the engineered α-crystal-
lins show variations in the extent of retardation, which are gen-
erally consistent with their relative effects in preventing the
amyloid fibril growth of Aβ (minor variations may partly be due
to the assay system and/or the nature of the protein). Thus these
results show that α-crystallin can interact with β2m fibrils as well.
The sHsp, αB-crystallin, can act both on the nucleation and
propagation processes of amyloid formation
It has earlier been proposed, based on the results with the
model system, apolipoprotein C-II, that α-crystallin interacts
with partially structured amyloidogenic precursors, inhibiting the
amyloid formation at the nucleation, rather than the elongation,
Figure 9 Effect of α-crystallins on the pH-induced dissociation of β2m
fibrils
β2m amyloid fibrils (prepared under acidic conditions) were placed in buffer A in the absence
or in the presence of 0.1 mg/ml of various α-crystallins and incubated at 37◦C. Fibrils present
in the sample at different time intervals were measured by ThT fluorescence. The results
shown represent the fraction of the fibril present after 60 min incubation. Error bars are
derived from data for three experiments. The inset shows the dissociation of the fibrils as
a function of time in the absence () or in the presence of 0.05 mg/ml () or 0.1 mg/ml (H17009)
αB-crystallin.
phase [21]. Our study on the mechanistic aspects of the prevention
of amyloid fibril growth of Aβ-(1–40) and β2m by α-crystallin
suggests that binding of the chaperone molecule to the fibril
nucleus, and prevention of the propagation process, is the pre-
dominant mechanism. This mechanism also suggests that the
observed differences in the relative efficiency of mutants and eng-
ineered α-crystallin variants towards insulin aggregation and Aβ-
(1–40) fibrillation are due to the involvement of aggregation-type
specific interactions. Such a phenomenon has not been invoked
earlier in the context of the function of α-crystallin. To the best
of our knowledge, this is the first demonstration of differential
action, providing a new insight into the mechanistic aspects
of chaperone action of α-crystallin involving different types of
interactions mediating the chaperone process towards amyloid
formation and amorphous aggregation (e.g. insulin aggregation)
of proteins. Our present study demonstrates that α-crystallins
can prevent the amyloid fibril propagation process as well. It
appears that, although α-crystallin can act on both nucleation and
propagation, its relative involvement in these two phases of
amyloid formation may depend on the nature of the amyloido-
genic species. If the amyloidogenic species exhibit significant
exposed hydrophobic surfaces (molten-globule-like state), α-
crystallin binds stably to the species [42,47,48] and thus pre-
vents the nucleation process itself. On the other hand, if the
amyloidogenic species has randomly coiled or extended con-
formation with less or no exposed hydrophobic surfaces [as in
the cases of Aβ-(1–40) and β2m], α-crystallins prevent the fibril
propagation process by binding to the fibril nucleus, as reported in
the present study.
Conclusions
Our study clearly shows that αB-crystallin prevents the amyloid
fibril growth of Aβ peptide, indicating that this sHsp has a
critical function in preventing the amyloid propagation process.
Since αB-crystallin does not form a stable complex with the Aβ
peptide, the mechanism of prevention of amyloid fibril growth
c© 2005 Biochemical Society
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of the Aβ peptide appears to be different from the mechanism of
prevention of amorphous aggregation of proteins, where α-crys-
tallin is known to form a stable complex. Our study shows that
preferential binding of the chaperone molecule to the fibril nucleus
is the predominant mechanism involved in its ability to prevent the
amyloid propagation of Aβ-(1–40). Thus our study should prove
useful in understanding the role of Hsps in protein conformational
diseases in general, and AD in particular.
B. R. thanks the JSPS (Japan Society for Promotion of Science), Japan, for the support of
a post-doctoral Fellowship.
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